Medical Countermeasures against Ricin Intoxication

Медицинские контрмеры при интоксикации рицином
Arnaud Avril, Christine Rasetti‐Escargueil
2023-01-20

Antibody-based therapyChemical inhibitorsMedical countermeasuresRicin intoxicationRicin vaccines
species. Ricin inhibits peptide chain elongation via disruption of the binding between elongation factors and ribosomes, resulting in apoptosis, inflammation, oxidative stress, and DNA damage, in addition to the classically known rRNA damage. Ricin has been used in traditional medicine throughout the world since prehistoric times. Because ricin toxin is highly toxic and can be readily extracted from beans, it could be used as a bioweapon (CDC B-list). Due to its extreme lethality and potential use as a biological weapon, ricin toxin remains a global public health concern requiring specific countermeasures. Currently, no specific treatment for ricin intoxication is available. This review focuses on the drugs under development. In particular, some examples are reviewed to demonstrate the proof of concept of antibody-based therapy. Chemical inhibitors, small proteins, and vaccines can serve as alternatives to antibodies or may be used in combination with antibodies.
1
Antibody-based therapies provide proof of concept, while chemical inhibitors, small proteins, and vaccines represent alternative or complementary strategies.
2
Combining antibodies with chemical inhibitors, small proteins, or vaccines may broaden therapeutic options against ricin intoxication.
3
No specific treatment for ricin intoxication is currently available, motivating development of targeted medical countermeasures.
4
Ricin disrupts elongation factor–ribosome binding, inhibiting peptide-chain elongation and causing apoptosis, inflammation, oxidative stress, and DNA damage.
5
Ricin’s extreme lethality and ready extraction from beans create a continuing global public-health concern and potential bioweapon threat.

Ricin intoxication in humans

Development and evaluation of specific medical countermeasures, including antibody-based therapies, chemical inhibitors, small proteins, and vaccines

Publication Details
Publication Date
2023-01-20
Journal
Publisher
ISSN
Cited by
27
Access Type
Author Information
Authors
Arnaud Avril
Christine Rasetti‐Escargueil
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat
Make a presentation
100%